<! –

->

October 28, 2018 – By Joseph Taylor

The release of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) results is expected on October 29 before market opening., According to Faxor. Analysts expect a difference of 30.77% or -0.09 from EPS of -0.13 $ in 2017. EPS growth of -43.75% is in line with Wall Street forecasts after -0.16 $ released last quarter. The stock fell 0.31% or $ 0.01 during the last trading session to $ 3.25. Brainstorm Cell Therapeutics Inc. has a volume of 33,158 shares. Since October 28, 2017, the BCLI has decreased 3.97% and is declining. BCLI underperformed the S & P 500 by 19.59%.

Brainstorm Cell Therapeutics Inc., a biotechnology company, is developing stem cell therapies for neurodegenerative disorders, including amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease and others. The company is worth 67.28 million dollars. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University. Finally, his profits were negative. The company's NurOwn technology is based on a new differentiation protocol that induces the differentiation of bone marrow-derived mesenchymal stem cells into neuron-bearing cells and secretes cells that release various neurotrophic factors, including the neurotrophic factor derived from the glia. neurotrophic factor derived from the brain. , vascular endothelial growth factor and hepatocyte growth factor for growth, survival and differentiation of developing neurons.

Some new information from Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) was published by: Benzinga.com, which published on October 27, 2018 "The Next Week in Biotechnology: Conferences, PDUFA Dates, Results of 39; Clinical Trials, Results and IPOs, "Globenewswire.com released Oct. 4, 2018" The BrainStorm Poster Receives Clinical Abstract Award at the NEALS Conference ", the next Globenewswire.com is" BrainStorm which Announces Third Quarter Financial Results and Provides Company Update on Monday, October 29, "October 17, 2018. Globenewswire.com article titled" BrainStorm Highlights Translational Data and Presentations Supporting the Platform " NUROWN® technology platform as a best-in … ».